Companies to collaborate on facilitating clinical trials in historically underserved regions.
Guardian Research Network (GRN) announced in a company press release that it has been joined by Clemson Rural Health to transform health outcomes in rural communities by conducting and facilitating clinical trials in historically underserved regions. GRN’s healthcare database is expected to help Clemson Rural Health bolster community health efforts to reduce premature mortality, decrease preventable hospitalizations and improve overall quality of life for local South Carolina patients.
"Partnering with Clemson Rural Health is a significant milestone for GRN," said Bruce Holstien, chairman, CEO, GRN. "Bringing this innovative team into our consortium demonstrates our unwavering commitment to improving access to cutting-edge studies in underserved communities. I look forward to the work we will accomplish together in our shared mission of driving community health advancements."
Reference: Clemson Rural Health Joins Forces with Guardian Research Network to Improve Community Health. PR Newswire. October 3, 2023. Accessed October 10, 2023. https://www.prnewswire.com/news-releases/clemson-rural-health-joins-forces-with-guardian-research-network-to-improve-community-health-301945161.html
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.